Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Market Conflict Next Week: What To Watch

2018-02-19 seekingalpha
After a wild and volatile 2 weeks, what to think about for the short trading week to come. (436-2)

FOLD / Amicus Therapeutics, Inc. 424B5 (Prospectus)

2018-02-17 sec.gov
Table of Contents   CALCULATION OF REGISTRATION FEE   Title of Each Class of Securities to be Registered   Amount to be Registered(1)   Proposed Maximum Offering Price Per Share   Proposed Maximum Aggregate Offering Price(1)   Amount of  Registration Fee(2)   Common stock, par value $0.01 per share   22,258,064   $ 15.50   $ 344,999,992.00   $ 42,952.50     (1) Includes an additional 2,903,225 shares of common stock that the underwriters have an option to purchase.

FOLD / Amicus Therapeutics, Inc. EX-99.2

2018-02-17 sec.gov
Exhibit 99.2     Amicus Therapeutics Prices Underwritten Offering of Common Stock   CRANBURY, NJ, February 15, 2018 — Amicus Therapeutics (Nasdaq: FOLD) today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are expected to be $300 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus.

FOLD / Amicus Therapeutics, Inc. EX-99.1

2018-02-17 sec.gov
Exhibit 99.1     Amicus Therapeutics Announces Public Offering of Common Stock   CRANBURY, NJ, February 14, 2018 — Amicus Therapeutics (Nasdaq: FOLD) today announced it has commenced a $250 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint lead book-running managers, Cowen and Leerink Partners LLC are acting as co-book-running managers, and BofA Merrill Lynch is acting as lead co-manager for the proposed offering.

FOLD / Amicus Therapeutics, Inc. EX-5.1

2018-02-17 sec.gov
Exhibit 5.1     3000 Logan Square Eighteenth and Arch Streets Philadelphia, PA  19103-2799 215.981.4000 Fax 215.981.4750   February 16, 2018   Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury, NJ 08512   Re:          Underwritten Public Offering   Ladies and Gentlemen:   This opinion is being furnished to you in connection with (i) the Registration Statement on Form S-3 (Registration No. 333-211005) (as amended from time to time, the “Registration Statement”), filed by Amicus Therapeutics,

FOLD / Amicus Therapeutics, Inc. EX-1.1

2018-02-17 sec.gov
Exhibit 1.1   AMICUS THERAPEUTICS, INC.   19,354,839 Shares of Common Stock, Par Value $0.01 per Share   Underwriting Agreement   February 15, 2018   J. P. Morgan Securities LLC   Goldman Sachs & Co. LLC   As Representatives of the     several Underwriters listed   in Schedule 1 hereto     c/o J. P. Morgan Securities LLC   383 Madison Avenue   New York, New York 10179       c/o Goldman Sachs & Co. LLC   200 West Street   New York, New York 10282       Ladies and Gentlemen:     Amicus Therapeutic

FOLD / Amicus Therapeutics, Inc. 8-K (Current Report)

2018-02-17 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of report (Date of earliest event reported): February 15, 2018   AMICUS THERAPEUTICS, INC. (Exact Name of Registrant as Specified in Charter)   Delaware (State or Other Jurisdiction of Incorporation)   001-33497   71-0869350 (Commission File Number)   (IRS Employer Identification No.

Amicus Therapeutics: Regulatory Update And Financing Add To Bull Case

2018-02-17 seekingalpha
Shares have come a long way since my original recommendation and are currently trading about 10% under the 52-week high. (23-1)

ROTY Edition 1 Volume 80: Adding To Select Positions And Continuing To Manage Risk

2018-02-16 seekingalpha
I remind readers of our biggest loser to date and why risk management has been key to ROTY`s success. (146-0)

FOLD / Amicus Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 4 TO SCHEDULE 13G (Passive Investment)

2018-02-15 sec.gov
Amendment No. 4 to Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)*     Amicus Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 03152W 10 9 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐

FOLD / Amicus Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - AMENDMENT NO. 4 TO SCHEDULE 13G (Passive Investment)

2018-02-15 sec.gov
Amendment No. 4 to Schedule 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)*     Amicus Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 03152W 10 9 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐

FOLD / Amicus Therapeutics, Inc. 424B5 (Prospectus)

2018-02-15 sec.gov
Table of Contents   Filed pursuant to Rule 424(b)(5) Registration No.: 333-211005   The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, nor are they soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.

FOLD / Amicus Therapeutics, Inc. / Redmile Group, LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
fold_13ga5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)*     Amicus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03152W109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) ý Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting per

FOLD / Amicus Therapeutics, Inc. / Redmile Group, LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
fold_13ga5.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)*     Amicus Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03152W109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) ý Rule 13d-1(b) ¨ Rule 13d-1(c) ¨ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting per

FOLD / Amicus Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - 3G (Passive Investment)

2018-02-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) AMICUS THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 03152W109 (CUSIP NUMBER) December 31, 2017 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1.


CUSIP: 03152W109